Jenburkt Pharmaceuticals Ltd — Others, 18-07-2025: AGM/EGM

Jenburkt Pharmaceuticals' 40th Annual General Meeting concluded with all proposed resolutions passing by the required majority. Shareholders approved the audited financial statements for FY 2024-25 and voted to declare a dividend of ₹18 per equity share (180%). Additionally, the re-appointment of Shri Ashish U. Bhuta as a Director and as the Chairman and Managing Director of the company was approved. The appointment of Secretarial Auditors and ratification of the Cost Auditor's remuneration for FY 2025-26 also received shareholder assent. These approvals reflect strong shareholder confidence in the company's financials and leadership.